Breast Cancer

A holistic integration of time series and static data present in the learning approach can lead to improved understanding of breast cancer outcomes.

In terms of cancer detected per 1000 MRI exams, the AI scoring method was close to 4 times more efficient vs traditional breast density measures.

SP-1-303’s ATM-activating and HDAC-inhibiting properties may overcome limitations seen in prior attempts to combine therapeutic agents and HDAC inhibitors.

Age and racial differences in subgroup analyses emphasize the need for strategies addressing Alzheimer’s/dementia risk factors and prevention of breast cancer.

A user-friendly “nudge” may provide a timely reminder to surgeons to consider the value of sentinel lymph node biopsy in older patients with breast cancer.

Findings from the PREVENT study show that bioimpedance spectroscopy use may reduce progression to chronic lymphedema compared with tape measure use.

Two dose-limiting toxicities were observed, and the maximum tolerated dose was not reached in a study evaluating FS-1502 safety, tolerability, and efficacy.

Data also show statistically meaningful improvements in endocrine symptoms and breast cancer–specific quality of life with acupuncture.

The new recommendation update modifies a 2020 ASCO guideline on the selection of optimal adjuvant chemotherapy and targeted therapy for breast cancer.

A ready-to-dilute formula of SH-105 has been approved by the FDA to treat breast and ovarian cancers.

Updated results from the POSITIVE trial found that patients younger than 35 years had a higher likelihood of achieving pregnancy during an endocrine therapy pause for HR-positive breast cancer.

Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.

Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.

Data from CAPItello-291 support the approval of capivasertib/fulvestrant for ER-positive, HER2-negative breast cancer in the European Union.